(Press-News.org) A new drug offers a breakthrough world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke, announced today by study lead Professor Stephen Nicholls, Director of the Monash University’s Victorian Heart Institute and Victorian Heart Hospital.
High levels of Lipoprotein(a), known as Lp(a) or spoken as ‘LP little a’, impact one in five people globally with no approved treatment currently on the market.
The trial demonstrated the success of Muvalaplin - the first oral drug ever developed to target Lp(a) - effectively lowering levels by up to 65%. It works by disrupting the ability for Lp(a) to form in the body.
Professor Stephen Nicholls, renowned cardiologist and Director of Monash University’s Victorian Heart Institute and the Victorian Heart Hospital at Monash Health, led the landmark research and trial, presented at the European Society of Cardiology Congress in Amsterdam today and published in JAMA.
Lp(a) is similar to LDL cholesterol, sometimes called ‘bad cholesterol’, but is more sticky, increasing risk of blockages and blood clots in arteries.
Common LDL lowering drugs such as statins don’t have the same lowering effect on Lp(a). Being largely genetic, Lp(a) is also difficult to control through diet, exercise and other lifestyle changes.
Although Lp(a) was discovered nearly 60 years ago there still aren’t any widely accessible treatments available to lower levels and reduce cardiovascular risk.
Professor Nicholls said the global research industry has been working on a targeted solution to treat elevated Lp(a) for the past decade, but advancements so far have been in difficult to administer injection-based therapies that are not yet on the market.
“When it comes to treating high Lp(a), a known risk factor for cardiovascular disease, our clinicians currently have no effective tools in their kit,” Professor Nicholls said.
“This drug is a gamechanger in more ways than one. Not only do we have an option for lowering an elusive form of cholesterol, but being able to deliver it in an oral tablet means it will be more accessible for patients.”
“Lp(a) is essentially a silent killer with no available treatment, this drug changes that.”
The trial was undertaken in collaboration with Cleveland Clinic and Eli Lilly, the drug will now continue into larger phase clinical trials. It may also have potential to be used in the treatment of other vascular and valve disease
Media contact
For more information on this story and to arrange an interview, please call 61 408378422
About the Victorian Heart Hospital
The Victorian Heart Hospital is Australia’s first dedicated cardiac hospital, improving health outcomes for people with – or at risk of – heart disease. It is the latest addition to the Monash Health group of hospitals, opening in February 2023.
In partnership with Monash University and housing the Monash Victorian Heart Institute, the Heart Hospital integrates clinical cardiology services, research and education to create a centre of excellence, raising the profile of cardiovascular research, treatment and training.
www.victorianhearthospital.org
About the Monash Victorian Heart Institute
Monash University’s Victorian Heart Institute is a health and medical research organisation based in the Victorian Heart Hospital. It unites multi-disciplinary experts to deliver excellence in cardiovascular research, education and training.
www.monash.edu/vic-heart-institute
About Monash Health
Monash Health is Victoria’s largest public health service and operator of the Victorian Heart Hospital. It provides safe, high-quality care to one-quarter of Melbourne’s population, across the entire lifespan, from pre-birth to end-of-life.
www.monashhealth.org
END
World first drug to target form of previously untreatable life-threatening ‘bad cholesterol’
New drug offers world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack/stroke
2023-08-28
ELSE PRESS RELEASES FROM THIS DATE:
An all-in-one surface design of copper nanowire assemblies to achieve ~100% defrosting efficiency
2023-08-28
Scientists at Dalian University of Technology propose a design of copper nanowire assemblies that can sufficiently enhance the de-icing and defrosting efficiency without conventional energy input. Specifically, the defrosting efficacy approaches 100%, a record-high value compared to reported studies.
The research, published in International Journal of Extreme Manufacturing, shows a simple electrochemical method for fabricating nanowire assemblies with controlled pattern, hierarchy, and size. This enables the simultaneous presentation of photothermal, thermal conductive, and superhydrophobic ...
Social justice for traditional knowledge holders will help conserve Europe’s nature
2023-08-28
It is well known that biodiversity of cultural landscapes is threatened by land abandonment and agricultural intensification. Traditional, low chemical and machinery input management systems have long been acknowledged for their diverse benefits to maintain and enhance biodiversity, however, the recognition of traditional knowledge, on which these traditional management practices are based, started only relatively recently. The recognition of traditional knowledge holders themselves is an even more recent phenomenon. A recently published paper aims to ...
Trial re-evaluates routine defibrillator implantation after myocardial infarction
2023-08-28
Amsterdam, Netherlands – 26 Aug 2023: Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial infarction survivors with heart failure still an adequate therapy for prevention of sudden cardiac death? The PROFID EHRA trial is set to answer this question in a large, multicentre, EU-funded study set to enrol the first patient this summer. The consortium of partners and colleagues involved in the trial, including the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC), will meet during ESC Congress 2023 to discuss the start of the study.
Myocardial ...
Price tag on cardiovascular disease in Europe higher than entire EU budget
2023-08-28
Amsterdam, Netherlands – 26 Aug 2023: Cardiovascular disease (CVD) cost the EU an estimated €282 billion in 2021, according to late breaking research presented at ESC Congress 2023.1 Health and long-term care accounted for €155 billion (55%) of these costs, equalling 11% of EU health expenditure. The analysis was a collaborative effort by the European Society of Cardiology (ESC) and the University of Oxford, UK.
Study author Dr. Ramon Luengo-Fernandez of the University of Oxford said: “CVD had a significant impact ...
NIH-funded study supports use of ECMO for critically ill patients with obesity
2023-08-28
NIH-funded study supports use of ECMO for critically ill patients with obesity
ECMO does not appear to complicate treatment for severe respiratory failure for adults with obesity
A National Institutes of Health-supported study suggests that adults with obesity may benefit from the use of extracorporeal membrane oxygenation (ECMO), an advanced form of breathing support, when in intensive care for respiratory failure. ECMO’s use was previously questioned for patients with obesity due to the belief that it may complicate ...
Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation
2023-08-28
About The Study: Muvalaplin was not associated with tolerability concerns and lowered lipoprotein(a) (Lp[a]) levels up to 65% following daily administration for 14 days in this first-in-human phase 1 study involving healthy participants. Lipoprotein(a) is associated with atherosclerotic disease and aortic stenosis. Longer and larger trials will be required to further evaluate safety, tolerability, and effect of muvalaplin on Lp(a) levels and cardiovascular outcomes.
Authors: Stephen J. Nicholls, M.B.B.S., Ph.D., of Monash University in Clayton, ...
Stevens researchers take aim at weather forecasters’ biggest blindspot
2023-08-28
Anyone who’s been caught in an unexpected downpour knows that weather forecasting is an imperfect science. Now, researchers at Stevens Institute of Technology are taking aim at one of meteorologists’ biggest blind spots: extremely short-term forecasts, or nowcasts, that predict what will happen in a given location over the next few minutes.
“This isn’t just about whether you should take your umbrella with you when you go on a walk,” said Temimi. “The forecasts that we’re missing – the ones that look ...
Projected outcomes of optimized statin and ezetimibe therapy in veterans with coronary artery disease
2023-08-28
About The Study: In this study of 111,000 U.S. military veterans with coronary artery disease, suboptimal lipid-lowering therapy was prevalent in the clinical setting. Optimization of statin therapy was projected to produce clinically relevant reductions in the risks of death and cardiovascular events. Despite a lesser lipid-lowering efficacy of ezetimibe, its widespread use on a population level in conjunction with optimized statin therapy may be associated with further meaningful reductions in cardiovascular risk.
Authors: Gregory G. Schwartz, M.D., Ph.D., of the Rocky Mountain Regional VA Medical Center in Aurora, Colorado, is the corresponding author.
To ...
COVID-19 virus is evolving rapidly in white-tailed deer
2023-08-28
COLUMBUS, Ohio – White-tailed deer across Ohio have been infected with the virus that causes COVID-19, new research has found – and the results also show that viral variants evolve about three times faster in deer than in humans.
Scientists collected 1,522 nasal swabs from free-ranging deer in 83 of the state’s 88 counties between November 2021 and March 2022. More than 10% of the samples were positive for the SARS-CoV-2 virus, and at least one positive case was found in 59% of the counties in which testing took place.
Genomic analysis showed that at least 30 infections in deer had been introduced by humans – ...
Are cannabis products safe and effective for reducing symptoms in children with cancer?
2023-08-28
A recent analysis of all relevant published studies reveals a lack of evidence to determine the dosing, safety, and efficacy of medical marijuana or cannabis-containing products for managing symptoms experienced by children with cancer. The analysis is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
Although treatments for childhood cancer have improved significantly, even leading to cures for many patients, many children still suffer from symptoms such as pain, anxiety, and weight loss related to cancer and its treatment. Over the last decade, cannabis ...
LAST 30 PRESS RELEASES:
Global prevalence of short-sightedness in children and teens set to top 740 million cases by 2050
Urgent rethink of bottled water’s huge and growing toll on human and planetary health
Women still missing out on treatment for their No 1 killer—cardiovascular disease
Palestinian education ‘under attack’, leaving a generation close to losing hope, study warns
Semaglutide improves outcomes for obese patients with common skin condition, new study shows
Could GLP1RA drugs lower high iron levels?
C-Path’s PKD outcomes consortium receives BAA Award for project to advance drug development tools for autosomal dominant tubulointerstitial kidney disease
New insights into hot carrier solar cells: Increasing generation and extraction
Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes
How emotion boosts memory for context
Specially designed video games may benefit mental health of children and teenagers
President Obama 2012 reelection linked to significantly better mental health in Black men — but only those with a college education
Finding the sweet spot: Machine learning reveals factors for successful crowdfunding
University of Houston unveils guideline to enhance treatment access for opioid use disorder in community pharmacies
Atmospheric methane increase during pandemic due primarily to wetland flooding
Violence, harassment from students is overwhelmingly ‘part of the job’ for Saskatchewan education sector workers
Thermal effects in spintronics systematically assessed for first time
Study shows rates of e-bike injuries rise fourfold and powered scooter injuries nearly double
Prediabetes during adolescence and young adulthood linked with likelihood of adverse pregnancy outcomes
Researchers discover new role of immune cells in eye health
Daniel R. Larson to receive 2025 Carolyn Cohen Innovation Award
James A. Glazier to receive 2025 Klaus Schulten and Zaida Luthey-Schulten Computational Biophysics Lecture Award
Better together: Gut microbiome communities’ resilience to drugs
More to munch on: The popcorn planet WASP-107b unveils new atmospheric details
Innovative electrolytes could transform steelmaking and beyond
Planting seeds for safer farming
Fruit-only diet improves bats’ immune response to viruses
Placebo pain relief and positive treatment expectations are not caused by dopamine
New guideline details how to manage CVD risk before, during & after noncardiac surgery
Silvia Cavagnero to receive 2025 Emily M. Gray Award
[Press-News.org] World first drug to target form of previously untreatable life-threatening ‘bad cholesterol’New drug offers world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack/stroke